Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex vs Placebo for Reversal of Profound Neuromuscular Blockade
NCT00758485Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2008
- Primary completion
- May 2009
- Modality
- Biodegradable Polymers, Small Molecules
01
Overview
A Phase 3 trial of Sugammadex in neuromuscular blockade (NMB), sponsored by Merck & Co.. Started Oct 2008; status: completed.
02
Drugs
Sugammadex
03
Conditions
neuromuscular blockade (NMB)
Beyond the preview
Go deeper on NCT00758485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00758485.